AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT
Rhea-AI Summary
Aimei Health Technology (Nasdaq: AFJK) received a Nasdaq notice on May 19, 2026, due to a delayed Form 10-Q for the quarter ended March 31, 2026, missing the May 15 deadline.
The notice has no immediate listing impact, but prolonged non-compliance could lead to Nasdaq delisting if the report is not filed or a compliance plan is not accepted.
Positive
- Nasdaq notice has no immediate effect on AFJK listing or trading
- Company has 60 days to file Form 10-Q or submit compliance plan
- Potential extension up to 180 days from due date if plan accepted
- Company working diligently and expects to regain listing rule compliance
Negative
- AFJK currently not in compliance with Nasdaq Listing Rule 5250(c)(1)
- Risk of Nasdaq delisting if compliance not timely regained
- Possible Nasdaq hearings panel process if compliance plan is not accepted
News Market Reaction – AFJK
In the May 21 session, AFJK declined 3.97%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.9% during that session. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Nasdaq non-compliance | Negative | +1.4% | Nasdaq notice for delayed Form 10-K and cure-period outline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history shows Nasdaq filing delays previously led to a positive price reaction despite negative compliance news.
Over the past months, Aimei Health Technology focused on its SPAC lifecycle and compliance. A prior Nasdaq notice on April 17, 2026 for a delayed Form 10-K filing still saw shares gain 1.42% over 24 hours, suggesting investors previously looked through filing delays. Today’s Nasdaq notice on the late Form 10-Q extends that compliance risk narrative, adding another delayed SEC report to the company’s record.
Key Terms
form 10-q regulatory
nasdaq listing rule 5250(c)(1) regulatory
u.s. securities and exchange commission regulatory
deficiency notification regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Quarterly Report was due on May 15, 2026.
The Notice has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company’s securities will be subject to delisting from Nasdaq.
Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Quarterly Report or submit a plan to Nasdaq to regain compliance with Nasdaq’s listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Quarterly Report’s due date to regain compliance. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.
The Company is working diligently to complete and file the Quarterly Report and expects to regain compliance with the Listing Rule.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the federal securities laws. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.
For investor and media inquiries, please contact:
Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022
Attention: Junheng Xie
Email: Xiejunheng@aimeihealth.com
